CTIS2024-514581-39-00进行中（未招募）1 期
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of theChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.
Ospedale San Raffaele S.r.l.0 个研究点目标入组 33 人开始时间: 2024年7月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
2 期
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of the
ChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.2024-514581-39-00Ospedale San Raffaele S.r.l., Ospedale San Raffaele S.r.l.33
进行中（未招募）
不适用
Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.Prostatic cancer patients who have received curative surgery.EUCTR2010-018770-20-NOOslo University Hospital30
已完成
1 期
Phase I study safety and immunogenicity of vaccination with XAGE1 long peptides in patients with advanced lung adenocarcinomaAdvanced lung adenocarcinomaJPRN-UMIN000026493Department of Immuno-Oncology, Kawasaki Medical School10
已完成
1 期
Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent pancreatic cancer to be refractory to chemotherapy by using new tumor antigen KIF20A and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatiopancreatic cancerJPRN-UMIN000002022Department of Gastroenterology, Juntendo University School of Medicine36
已完成
1 期
Phase I / II clinical trial of peptide vaccination therapy for unresectable / recurrent gastric cancer to be refractory to chemotherapy by using new tumor antigen URLC10 and A2402 restrictive epitope peptide of the VEGFR1 origin related gene of tumor vascularizatiogastric cancerJPRN-UMIN000002409Department of Gastroenterology, Juntendo University School of Medicine36